Abstract 1009P
Background
Advanced hepatocellular carcinoma (HCC) is a highly lethal disease with limited treatment options. The use of first-line (1L) systemic therapies showcase improved overall survival and quality of life. This study aimed to compare the objective response rate (ORR) of various systemic therapies for advanced HCC in 1L setting using a network meta-analysis.
Methods
A systematic literature review (SLR) and network meta-analysis (NMA) of randomized controlled trials (RCTs) was conducted to assess the efficacy of 1L systemic therapies for advanced HCC. Multiple databases, including PubMed, Embase, and the Cochrane Library were searched for relevant studies. The primary outcome of interest was the ORR of each therapy compared to placebo. The results were obtained for both fixed and random-effect models to estimate each therapy's relative risk (RR) and 95% credible intervals (CrI).
Results
A total of 12 RCTs met the inclusion criteria. The combination therapy of sintilimab + IBI305 had the highest ORR, with an RR of 13.6 (95% CrI: 3.69, 55.67) using fixed-effect and RR of 14.13 (95% CrI: 0.82, 120.1) using random-effect models. SUCRA values ranged from 0.075 for placebo to 0.761 for sintilimab + IBI30. SUCRA rankings were generally better for combination therapies followed by mono-therapies and placebo.
Conclusions
The NMA revealed that the combination therapies had the highest ORR among the systemic therapies in the 1L setting. The SUCRA values confirmed the high probability of these treatments ranking higher in terms of ORR and can be used to support treatment decision-making in clinical practice.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
G. Kaur, B. Singh, S. Attri, A. Sharma, P. Rai, S. Pandey: Financial Interests, Personal, Full or part-time Employment: Pharmacoevidence.
Resources from the same session
842P - Multicenter real-world study of newly diagnosed advanced-stage extranodal natural killer/T cell lymphoma (ENKTL): Proposal for intensive therapy
Presenter: Yu-Ce Wei
Session: Poster session 18
844P - Progression -free survival prediction of multiple myeloma patients in five European countries using machine learning models
Presenter: Maria Luisa Pleguezuelo Witte
Session: Poster session 18
845P - A machine learning based clinical platform for cancer subtyping and data integration in hematological malignancies
Presenter: Michelle Tang
Session: Poster session 18
846P - Artificial intelligence-driven identification of onco-hematology patients who may develop severe COVID-19
Presenter: Souad Assaad
Session: Poster session 18
847P - Fatal infections among leukemia patients
Presenter: Huijie Zhou
Session: Poster session 18
848P - Mortality after rasburicase vs allopurinol anti-hyperuricemia monotherapy in patients with liquid tumors
Presenter: Mitchell Cairo
Session: Poster session 18
849P - Long non-coding RNA signatures and their role in the progression of childhood T cell acute lymphoblastic leukemia
Presenter: Pankaj Sharma
Session: Poster session 18
850P - A zebrafish model of MYC-driven acute myeloid leukemia reveals that neutrophil resistance to oncogenic transformation depends on their ability to promote PP2A-mediated MYC proteasomal degradation
Presenter: Anna Maria Luciano
Session: Poster session 18
851P - Characterization of a zebrafish model of MYC-driven acute myeloid leukemia
Presenter: Anna Maria Luciano
Session: Poster session 18
852P - c-MAF-driven metabolic reprogramming mediates H3K27 hyperacetylation to regulate super enhancer-associated genes
Presenter: Phyllis SY Chong
Session: Poster session 18